MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21873/cgp.20373

Медицинская библиотека · Cancer genomics & proteomics · 2023

Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer.

Masuda Takaaki, Ueo Hiroaki, Okumura Yuta, Kai Yuichiro, Ando Yuki, Masuguchi Ken, Kitagawa Miwa, Kitagawa Akihiro, Hayashi Naoki, Tsuruda Yusuke, Hisamatsu Yuichi, Suehiro Shuji, Ohmura Hirofumi, Fujiyoshi Kenji, Tanaka Fumiaki, Mimori Koshi

СтатьяПеревод в очереди

Аннотация

BACKGROUND/AIM: The immune system has a pivotal role in modulating the response to chemotherapy in breast cancer (BC). However, the immune status during chemotherapy remains unclear. We evaluated the sequential changes in peripheral systemic immunity markers in BC patients treated with various chemotherapeutic agents.

MATERIALS AND

METHODS

We examined the correlation between the peripheral systemic immunity markers, neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC) and the local cytolytic activity (CYT) score obtained by quantitative reverse-transcription polymerase chain reaction of 84 preoperative BC patients. Next, we observed the sequential changes in the peripheral systemic immunity markers during treatment with four anticancer drugs: oral 5-fluorouracil derivative; S-1, epirubicin plus cyclophosphamide; paclitaxel plus the anti-vascular endothelial growth factor antibody bevacizumab, and eribulin in 172 HER2-negative advanced BC patients. Finally, we examined the correlation between the changes in the peripheral systemic immunity markers, time to treatment failure (TTF) and progression-free survival (PFS).

RESULTS

A negative correlation was found between ALC and NLR. ALC-low and NLR-high cases were positively associated with CYT score-low cases. The ratio of ALC-increase and NLR-decrease varies depending on the anticancer drugs used. The responder group (TTF ≥3 months) had a higher NLR-decrease ratio than the nonresponder group (TTF <3 months). Patients with a high NLR-decrease ratio showed higher PFS.

CONCLUSION

The change in ALC or NLR varies according to the anticancer drugs, suggesting differential immunomodulatory effects of the drugs. Furthermore, the change in NLR reflects the therapeutic efficacy of chemotherapy in advanced BC.

Для цитирования: Masuda Takaaki, Ueo Hiroaki, Okumura Yuta, Kai Yuichiro, Ando Yuki, Masuguchi Ken, Kitagawa Miwa, Kitagawa Akihiro, Hayashi Naoki, Tsuruda Yusuke, Hisamatsu Yuichi, Suehiro Shuji, Ohmura Hirofumi, Fujiyoshi Kenji, Tanaka Fumiaki, Mimori Koshi. Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer.. Cancer genomics & proteomics. 2023. DOI: 10.21873/cgp.20373.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.